US FDA approves BioMarin's gene therapy for hemophilia A

Sangamo Therapeutics

29/06/2023 19:38

The U.S. Food and Drug Administration on Thursday approved
BioMarin Pharmaceutical's  BMRN.O  gene therapy for hemophilia
A, the company said, giving patients with the inherited bleeding
disorder an option to reduce regular blood infusions. 

 (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru;
Editing by Krishna Chandra Eluri)
 ((Khushi.Mandowara@thomsonreuters.com;))